Artivion, Inc. (NYSE:AORT – Get Rating) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 3,170,000 shares, a decline of 6.2% from the February 28th total of 3,380,000 shares. Currently, 8.3% of the shares of the stock are sold short. Based on an […]
/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate.
Fourth Quarter and Recent Business Highlights: Achieved revenue of $79.4 million in the fourth quarter of 2022 versus $79.4 million in the fourth quarter of.